FDA granted Orphan Drug Designation to stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer.
The Parker Institute for Cancer Immunotherapy and National Resilience Inc. announced a five-year strategic alliance to develop next-generation cancer therapies.
Dana-Farber Cancer Institute, Gustave Roussy, and L’Institut Servier signed a cooperation agreement to foster collaboration among oncology researchers.
FDA announced the launch of the “Next Legends” Youth E-cigarette Prevention Campaign, which aims to protect youth from the dangers of tobacco use. The campaign will educate American Indian/Alaska Native youth, ages 12-17, about the harms of vaping through unique branding and tailored messaging.
FDA approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo plus Yervoy (ipilimumab) as first-line treatments for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, regardless of PD-L1 status.
FDA granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
FDA approved for priority review the Biologics License Application for Omblastys (omburtamab) in the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.
FDA granted Fast Track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.
Blue Note Therapeutics and OncoHealth have partnered to deliver oncology-specific mental health care.
C2i Genomics and Karkinos Healthcare have partnered to co-develop the minimal residual disease market in India.
